|Product Overview:||Recombinant human Proprotein Convertase 9/PCSK9 (Gln31-Gln152 & Ser153-Gln692) with a C-terminal 10-His tag protein was expressed in mouse myeloma cell line.|
|Description:||This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia.|
|Predicted N Terminal:||Ser153 (mature form); No results obtained for pro domain, Gln31 inferred from enzymatic pyroglutamate treatment revealing Glu32|
|Bio-activity:||Measured by its binding ability in a functional ELISA. When Recombinant Human LDL R is coated at 2 µg/mL, Recombinant Human Proprotein Convertase 9/PCSK9 binds with an ED50 of 70-420 ng/mL.|
|Molecular Mass:||Predicted Molecular Mass: 14 kDa & 59 kDa
SDS-PAGE: 19 kDa & 66 kDa, reducing conditions
|Endotoxin:||<1.0 EU per 1 μg of the protein by the LAL method.|
|Purity:||>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.|
|Storage:||Avoid repeated freeze-thaw cycles.
6 months from date of receipt, -20 to -70 centigrade as supplied.
3 months, -20 to -70 centigrade under sterile conditions after opening.
|Storage Buffer:||Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol.|
|Official Symbol:||PCSK9 proprotein convertase subtilisin/kexin type 9 [ Homo sapiens (human) ]|
|Synonyms:||EC 3.4.21; EC 184.108.40.206; FH3; FH3neural apoptosis regulated convertase 1; HCHOLA3; hypercholesterolemia, autosomal dominant 3; LDLCQ1; NARC-1; NARC-1convertase subtilisin/kexin type 9 preproprotein; NARC1EC 3.4.21.-; Neural apoptosis-regulated convertase 1; PC9; PCSK9; Proprotein Convertase 9; proprotein convertase subtilisin/kexin type 9; Subtilisin/kexin-like protease PC9|